MedTrace Logo

Social Cognition Dysfunctions in Parkinson's Disease

NCT05230095 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2024-02-07

No results posted yet for this study

Summary

Parkinson's disease (PD) is usually responsible of cognitive and behavioral non-motor signs with a major impact on the quality of life. Social cognition is a complex system relying on emotion recognition (neurons mirror system (NMS)), the theory of mind (with its two parts: emotional and cognitive), but also on the social and cultural environment and the personal history. The first step in this model is represented by the NMS, which seems to be altered in PD patients for both positive and negative emotions as shown in our preliminary study. The investigator purpose is to investigate the role of the treatment (levodopa and deep brain stimulation) on the functioning of the NMS

Conditions

  • Parkinson Disease

Interventions

BEHAVIORAL

social cognition tests

The evaluation of social cognition will be carried out using questionnaires and a point lights computer test. During the computer test, participants have to watch several short sequences of interactions between two silhouettes and give an interpretation of the scene. Patients will be evaluated twice: one time before the surgery and a second time 1 year after surgery. Healthy volunteers will be evaluated only one time.

BEHAVIORAL

Quality of life self-questionnaire

Quality of life will be assessed using a self-administered questionnaire in the patients group only.

Sponsors & Collaborators

  • Hospices Civils de Lyon

    lead OTHER

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2024-01-23
Completion
2024-01-23

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05230095 on ClinicalTrials.gov